drugset / Trial / NCT04086342
CHI-902 for Treatment of Social Anxiety Disorder
Phase 2
Withdrawn
Canopy Growth Corporation
Centre for Addiction and Mental Health · collabMcMaster University · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
No substantial clinical trials of Cannabidiol (CBD) in Social Anxiety Disorder (SAD) have yet been conducted. This randomized doubleblind, placebo-controlled trial of CBD in adults with SAD will evaluate the efficacy, tolerability and safety of CBD oil (CHI-902) in SAD. In addition, the effects of treatment with CHI-902 on the Endocannabinoid System (ECS) will be assessed by evaluating peripheral endocannabinoids (Arachidonoylethanolamide/Anandamide (AEA) and 2-Arachidonoyl glycerol (2-AG)) before and after treatment.
Timeline
- Start
- 2020-01-24
- Primary completion
- 2021-01-26
- Completion
- 2021-01-26
Outcome
Outcome not reported
Stopped: “Changes in pipeline”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | CHI-902 | Unknown | 300 mg | Oral |